(Q33349378)

26 July 2017

title

Hematologic disorders associated with hepatitis C virus infection and their management (English)

1 reference

26 July 2017

1 reference

1 reference

Douglas T Dieterich

1

1 reference

26 July 2017

Jerry L Spivak

series ordinal

2

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

Clinical Infectious Diseases

26 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

26 July 2017

volume

37

1 reference

26 July 2017

issue

4

1 reference

26 July 2017

page(s)

533-541

1 reference

Hepatitis C: a brief clinical overview

26 July 2017

cites work

1 reference

The significance of antibody to hepatitis C virus in patients with chronic hepatitis B.

21 January 2018

1 reference

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria

21 January 2018

1 reference

Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

The blood in systemic disorders

21 January 2018

1 reference

Autoimmune hemolytic anemia in treatment-naïve chronic hepatitis C infection

21 January 2018

1 reference

Chronic hepatitis C virus infection associated with primary warm-type autoimmune hemolytic anemia

21 January 2018

1 reference

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

High sustained response rate in patients with histologically mild (low grade and stage) chronic hepatitis C infection. A randomized, double blind, placebo controlled trial of interferon alpha-2b with and without ribavirin.

21 January 2018

1 reference

Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials.

21 January 2018

1 reference

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

21 January 2018

1 reference

Interferon-alpha plus ribavirin for 12 months increases the sustained response rates in chronic hepatitis C relapsers.

21 January 2018

1 reference

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

21 January 2018

1 reference

Advances in treatment of chronic hepatitis C: 'pegylated' interferons

21 January 2018

1 reference

A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C.

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha-2a (40 kD): a review of its use in the management of chronic hepatitis C.

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C advances in antiviral therapy: what is accepted treatment now?

21 January 2018

1 reference

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

Hematological and bone marrow effects of ribavirin in rhesus monkeys.

21 January 2018

1 reference

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

21 January 2018

1 reference

Factors influencing ribavirin-induced hemolysis

21 January 2018

1 reference

Human immunodeficiency virus infection, anemia, and survival

21 January 2018

1 reference

Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. EuroSIDA study group

21 January 2018

1 reference

Autoimmune thrombocytopenia induced by PEG-IFN-alpha2b plus ribavirin in hepatitis C.

21 January 2018

1 reference

Epoetin alfa therapy for anaemia in HIV-infected patients: impact on quality of life

21 January 2018

1 reference

Treatment of ribavirin/interferon-induced anemia with erythropoietin in patients with hepatitis C.

21 January 2018

1 reference

A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity

21 January 2018

1 reference

Fatigue in patients with chronic hepatitis C.

21 January 2018

1 reference

Fatigue is associated with high circulating leptin levels in chronic hepatitis C.

21 January 2018

1 reference

Treatment of hepatitis C related thrombocytopenia with interferon alpha

21 January 2018

1 reference

HCV-associated thrombocytopenia: clinical characteristics and platelet response after recombinant alpha2b-interferon therapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/376971

1 reference

26 July 2017

1 reference